Early research (Phase 1)Active Not RecruitingNCT05509790What this trial is testingLY3484356 in Chinese Participants With Advanced Breast CancerWho this might be right forBreast Neoplasms Eli Lilly and Company 17
Early research (Phase 1)Looking for participantsNCT07524322What this trial is testingStudy of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsWho this might be right forBreast CancerOvarian CancerEndometrial Cancer+6 more Regor Pharmaceuticals Inc. 63
Testing effectiveness (Phase 2)WithdrawnNCT00627627What this trial is testingEvaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast CancerWho this might be right forBreast Cancer MedImmune LLC 56
Not applicableApproved For MarketingNCT04100694What this trial is testingEarly Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorWho this might be right forNRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more Merus B.V.
Not applicableLooking for participantsNCT07455188What this trial is testingA Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer Zhejiang Cancer Hospital 600
Large-scale testing (Phase 3)Study completedNCT01007942What this trial is testingDaily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast CancerWho this might be right forHER2/Neu Over-expressing Locally Advanced Breast CancerMetastatic Breast Cancer Novartis Pharmaceuticals 569
Post-approval studies (Phase 4)WithdrawnNCT03988114What this trial is testingAbemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast CancerWho this might be right forMetastatic Breast Cancer Eli Lilly and Company
Testing effectiveness (Phase 2)Study completedNCT02129556What this trial is testingAnti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast CancerWho this might be right forMetastatic Breast Cancer ETOP IBCSG Partners Foundation 58
Testing effectiveness (Phase 2)Study completedNCT01565200What this trial is testingHER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1Who this might be right forHER-2 Positive Breast Cancer Jules Bordet Institute 90
Early research (Phase 1)Active Not RecruitingNCT04042701What this trial is testingDS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerWho this might be right forBreast CancerNon-small Cell Lung Carcinoma Daiichi Sankyo 115
Early research (Phase 1)Study completedNCT02586675What this trial is testingTEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast CancerWho this might be right forBreast CancerBreast Cancer - FemaleBreast Cancer - Male H. Lee Moffitt Cancer Center and Research Institute 7
Large-scale testing (Phase 3)Active Not RecruitingNCT02115282What this trial is testingExemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticWho this might be right forAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+4 more National Cancer Institute (NCI) 608
Early research (Phase 1)Study completedNCT02088684What this trial is testingStudy of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast CancerWho this might be right forBreast Cancer Novartis Pharmaceuticals 70
Testing effectiveness (Phase 2)UnknownNCT02983071What this trial is testingG1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerWho this might be right forCarcinoma, Ductal, BreastBreast CancerBreast Neoplasm G1 Therapeutics, Inc. 102
Post-approval studies (Phase 4)Study completedNCT02445586What this trial is testingSafety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 52
Early research (Phase 1)Study completedNCT01576666What this trial is testingPhase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid TumorsWho this might be right forDose EscalationSafetyPreliminary Efficacy+9 more Novartis Pharmaceuticals 120
Early research (Phase 1)UnknownNCT04660929What this trial is testingCAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsWho this might be right forHER2-positiveAdenocarcinomaBile Duct Cancer+28 more Carisma Therapeutics Inc 48
Testing effectiveness (Phase 2)Looking for participantsNCT05150691What this trial is testingA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsWho this might be right forHER2-positive Advanced Solid Tumor DualityBio Inc. 796
Testing effectiveness (Phase 2)Looking for participantsNCT07612891What this trial is testingEvaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid TumorWho this might be right forBreast Cancer (Locally Advanced or Metastatic)Advanced Solid CancersMetastatic (Stage IV) Breast Cancer+2 more Shenzhen Ionova Life Sciences Co., Ltd.
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117What this trial is testingEvaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Who this might be right forLocally Advanced or Metastatic Malignant Solid Tumors Astellas Pharma Global Development, Inc. 329